Mereo Biopharma Group PLC
NASDAQ:MREO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
UK |
|
System Research Co Ltd
TSE:3771
|
JP |
|
S
|
San Miguel Corp
OTC:SMGBF
|
PH |
|
Dr. Lal PathLabs Ltd
BSE:539524
|
IN |
|
Pantaflix AG
XETRA:PAL
|
DE |
|
S
|
Sundaram Clayton Ltd
NSE:SUNCLAYLTD
|
IN |
|
B
|
Baroque Japan Ltd
TSE:3548
|
JP |
|
Brookfield Asset Management Inc
NYSE:BAM
|
CA |
|
Herc Holdings Inc
NYSE:HRI
|
US |
Mereo Biopharma Group PLC
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).
